

Reference:	FOI.20091.26
Subject:	Atopic Dermatitis
Date of Request:	1 April 2026

Requested:

1. How many patients were treated in the last 4 months (December to March 2026) by the dermatology department with each of the following products:
 - Abrocitinib
 - Acitretin
 - Alitretinoin
 - Azathioprine
 - Baricitinib
 - Ciclosporin
 - Dupilumab
 - Lebrikizumab
 - Methotrexate
 - Mycophenolate mofetil
 - Pimecrolimus
 - Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
 - Tacrolimus ointment
 - Tralokinumab
 - Upadacitinib
 - Nemolizumab

2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department
 - Abrocitinib
 - Baricitinib
 - Dupilumab
 - Lebrikizumab
 - Tralokinumab
 - Upadacitinib
 - Nemolizumab

*Patients are considered 'new patients initiated' on a treatment if they have not been previously treated with any of the other named treatments above since 1st April 2025 prior to initiation.

e.g. Patient initiated on Lebrikizumab in Dec 2025 - March 2026 (has not previously been treated with Abro, Bari, Dupi, Tralo, Upada, Nemo since March 2025)

3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:
 - 6 months to 5
 - Age 6-11
 - Age 12-17
 - Age 18 and above

4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:
- Dupilumab
 - Nemolizumab

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low number (less than 5). Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table below, the number of patients that were issued with the named biologic medications by the Dermatology department, during the period 1 December 2025 to 31 March 2026.

Medication	Number
Abrocitinib	*
Acitretin	59
Alitretinoin	6
Azathioprine	15
Baricitinib	0
Ciclosporin	13
Dupilumab	152
Lebrikizumab	5
Methotrexate	120
Mycophenolate mofetil	17
Pimecrolimus	0
Phototherapy (UVB or PUVA) - for Atopic Dermatitis only	0
Tacrolimus ointment	*
Tralokinumab	6
Upadacitinib	10
Nemolizumab	*

2. The UHB provides within the table overleaf, the number of patients initiated on the named biologic medications by the Dermatology department, during the period 1 December 2025 to 31 March 2026.

Medication	Number
Abrocitinib	0
Baricitinib	0
Dupilumab	19
Lebrikizumab	*
Tralokinumab	0
Upadacitinib	0
Nemolizumab	0

3. The UHB provides within the table below, the number of patients in each of the listed age groups that were issued with the biologic medications listed in question 1, during the period 1 December 2025 to 31 March 2026.

Age Group	Number
6 months - 5	6
Age 6 – 11	15
Age 12 – 17	25
Age 18 and above	362

4. The UHB provides within the table below, the number of patients treated by the Dermatology department for Prurigo Nodularis, with the listed medications, during the period 1 December 2025 to 31 March 2026.

Medication	Number
Dupilumab	*
Nemolizumab	0